IP
Ipsen S.A.
IPSEY · OTC
$41.90 +2.47% (+$1.01)
1M -8.73%
Market Cap 49.2B €
P/E Ratio 115.33x
Div. Yield 1.11%
ROE 9.79%
Bulios Fair Price
$31.18
25.6% downside
Current Price
$41.9
Undervalued Fair Value Overvalued
According to Bulios Fair Price, IPSEY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
2 /100
Expensive EV/EBITDA 46.05x
P/S 13.95x
P/B 11.36x
Growth
38 /100
Stable Rev. growth 3.81%
FCF growth 11.36%
Book val. growth 9.10%
Profitability
90 /100
Strong Net margin 12.09%
Op. margin 20.30%
FCF margin 28.10%
Quality
50 /100
Average ROE 9.79%
ROA 6.16%
Asset turnover 0.51x
Debt
100 /100
Low Current ratio 1.96x
Int. coverage 20.67x
Net debt/EBITDA -0.44x
Stability
70 /100
Stable Rev. volatility 4.73%
EPS volatility 34.35%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about IPSEY
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
David G. Loew
Employees
5,535
Headquarters
Paris
Upcoming events
11 FEB
Earnings
Upcoming earnings report